AIC THERAPY DOSING · 2021. 1. 9. · MEGAGEN 74 CARTIGEN 75 ALZIGEN 76 DENTIGEN 77 OSSO JR 78. 1...

A

AIC THERAPY

DOSING PROTOCOL2020

A guideline for participating physicians only

Version 1.0

CONTENTSDISCLAIMER 1AIC THERAPY PROTOCOL 2TREATMENT GOALS OF AIC THERAPY 3UNDERSTANDING YOUR AIC PRESCRIPTION 4NO CAUSE FOR HYPERCALCEMIA 5TIME & WATER FOR PROPER AIC INTAKE 6AIC STORAGE 7DOSAGE FOR DEGENERATIVE DISEASE 9DOSAGE FOR CANCER 10AIC THERAPY FOR CANCER 11AIC THERAPY PHASE ONE 12AIC THERAPY PHASE TWO 13AIC THERAPY PHASE THREE 14AIC CANCER THERAPY PHASES 15SAMPLE AIC DOSAGE PROTOCOL 16PHYSIOLOGICAL EFFECTS OF AIC 22AIC OVERDOSE 23IMPROVED EFFICACY WITH INCREASED DOSAGE 24STARTING WITH A STRONG DOSE 25AIC IS A SYSTEMIC THERAPY 26CRITICAL 3 MONTH MINIMUM TREATMENT 27CRITICAL 3 MONTH PERIODS OF CASE STUDY 28MOLLY’S SUCCESS STORY 29HEALING REACTIONS, NOT SIDE EFFECTS 30TYPES OF HEALING REACTIONS 31MINIMIZING HEALING PAINS 32CONTRAINDICATIONS 33COMMONLY TREATED CONDITIONS 34DOSING FOR CHILDREN 35DOSING FOR CKD PATIENTS 36MARAGEN IV INFUSION 37

MARAGEN IV VS. ORAL MARAGEN 38MARAGEN IV DOSING PROTOCOL 39NEBULIZING MARAGEN 40MARAGEN VS MEGAGEN 41INTRODUCTION TO NEW CALCIUM CARBONATE 44EXPERTISE OF PRONUVIA-CBHI TEAM 45PRONUVIA SUCCESS STORY 46CBHI RESEARCH PARTNER ORGANIZATIONS 47PROMISING ANIMAL OSTEOPOROSIS & CANCER TRIALS 48LACTIC ACID REDUCTION CLINICAL CASES 49PROMISING HUMAN BONE HEALTH CLINICAL CASES 50FUNCTIONS OF CALCIUM IN THE BODY 51ONLY AIC PROVIDES CALCIUM IN IONIC FORM 52AIC UTILIZES SIGMA ANTI-BONDING 53AIC EASILY RELEASES CALCIUM IONS 54AIC IS ABSORBED BY DIFFUSION & OSMOTIC PRESSURE 55ACTIVE VS. PASSIVE ABSORPTION 56SAMPLE CLINICAL CASES ACHIEVED WITH AIC THERAPY 57WHAT DO OUR PATIENTS SAY? 58DE-CALCIFICATION EFFECTS OF AIC 59FRACTURE HEALING EFFECTS OF AIC 60SAMPLE CLINICAL BONE DENSITY INCREASE 61CLINICAL TRIAL SAMPLE 1 63CLINICAL TRIAL SAMPLE 2 67CLINICAL TRIAL SAMPLE 3 70AIC THERAPY PRODUCT LINE UP 72MARAGEN 73MEGAGEN 74CARTIGEN 75ALZIGEN 76DENTIGEN 77OSSO JR 78

1

DISCLAIMERPronuvia thanks participating doctors, clinics, and health care practitioners for making AIC therapy avail-able to consenting patients who are looking for an adjunct, adjuvant, and alternative treatments.

Please note that Pronuvia hereby makes no medical claims to treat or cure any diseases. AIC-applied products are registered as dietary supplements, and the health benefits are from our body’s natu-ral response to addressing ionic calcium deficiency through AIC therapy. At the recommended dosage, AIC slightly elevates blood ionic calcium concentration within the safe range to trigger healthy responses. Simply put, AIC therapy is a nutritional therapy based on ionic calcium.

Pronuvia makes only one scientific claim that AIC (Sigma-Antibonding Calcium) applied-products when taken orally deliver calcium in ionic form, which in turn triggers a cascade of physiological benefits. Utilizing these physiological reactions in treating diseases at any capacity is solely at the discretion of participating physicians.

Pronuvia distributes AIC applied products only through licensed physicians, clinics, and health care practitioners, and the use of AIC-applied products for patients is solely the responsibility of participat-ing practitioners and consenting patients. Pronuvia, as a company, does not treat patients directly nor offer any health advice. Pronuvia encourages patients to make their own health care decisions based upon their research and in partnership with a qualified health care professional.

2

INTRODUCTION TO AIC THERAPY PROTOCOLPronuvia’s AIC therapy utilizes the world’s first calcium-ion-delivery-system called Sigma Anti-Bonding Molecule Calcium Carbonate (AIC-CaCO3), invented by CBHI, a research institute based in BC, Canada.

AIC therapy employs ionic calcium supplementation to successfully elevate the level of physiologically active plasma ionic calcium, triggering our body’s natural functions to build strong bones and re-establish healthy calcium homeostasis. Appropriating influx and efflux of calcium ion modifies mitochondrial functions, improves oxidative stress, and normalizes cellular calcium signaling, which is the key to treating chronic degenerative diseases.

By providing calcium in ionic form, which is the only physiologically active form of calcium in our body, AIC therapy addresses ionic calcium deficiency better than pro-tein-bound calcium supplied through diet and popular calcium supplements avail-able in the market today.

This dosage protocol guideline provides participating physicians with suggestions on how Pronuvia’s AIC-applied products can be utilized effectively in treating com-municable and degenerative diseases. By eliciting calcium-sensitive physiological responses that counteract the root cause of diseases, AIC therapy is recommended as a part of a more comprehensive treatment plan. Ionic calcium treatment is still evolving and is undergoing clinical evaluations by participating researchers and doctors. Pronuvia appreciates many participating physicians for providing inputs in fine-tuning the dosage protocol.

3

TREATMENT GOALS OF AIC THERAPYAIC is a nutritional supplement providing calcium in a physiologically-active ionic form, which is utilized by our body without the need for conversion from its default protein form. Because of the role of ionic calcium in communication as a cellular signaling agent, neurotransmitter, and second messenger, our body has mechanisms to pre-cisely regulate the concentration of ionic calcium in the blood, extracellular spaces, and intracellular spaces for clear, undistorted signaling.

However, with aging, poor nutrition, unhealthy lifestyle, and accumulation of toxins from food and the environment, the delicate balance of calcium homeostasis starts to tip over, causing both cellular and systemic communications breakdowns, which in turn triggers the onset of a host of degenerative diseases.

Being the world’s first true ionic-calcium supplement, AIC triggers our body’s natural calcium-sensitive responses that help to restore the delicate balance of calcium homeo-stasis, which normalizes cellular communication, restores mitochondrial functions, and reduces oxidative stress. Healthy cells lead to healthy tissues, organs, and systems, and this cells-to-systems overhaul by AIC therapy is the way how the therapy helps to reverse degenerative diseases and improve quality of life.

4

UNDERSTANDING YOUR AIC PRESCRIPTIONOur body’s calcium homeostatic system safely and effectively regulates fluctuations of serum plasma ionic calcium concentrations, and AIC therapy provides the dosage intake well within the healthy range. AIC has no known side effects or contraindica-tions with known drugs, and for many years doctors and health practitioners around the world employed AIC as an adjunct or adjuvant treatment or even as a stand-alone primary treatment for their patients with much success.

Because of AIC’s usage in treating many severe diseases alongside both conventional and integrative treatments, AIC therapy is provided only through participating doc-tors with proper knowledge and training in AIC. Prescribing effecting dosage, manag-ing patient’s expectations, and monitoring progress are required for AIC therapy to maximize the patient benefits and to arrive at the desired health outcome without complications.

For these reasons, AIC-applied products are not sold over the counter or online, unlike other supplements, but are dispensed only under the care of participating health practitioners. AIC is to be treated as therapy with strict protocols and should only be prescribed as such.

5

NO CAUSE FOR HYPERCALCEMIA

• AIC adds only 5mg-7.6mg of Ca2+ to 5 L of blood (average adult), which increases the concentration of ionic calcium only by 0.15mg/dL max.

• Hypercalcemia is classified with plasma ionized calcium levels above 5.6 mg/dL (Mild Hypercalcemia : Ca2+ @ 5.6 ~ 8mg/dL)

• The total amount of Ca2+ in an average adult is about 250mg. AIC only adds about 5-7.6mg, which is about 2-3% increase, well within the safe range.

• Hyperparathyroidism causes hypercalcemia. The thyroid triggered by AIC results in the activation of osteoblast, which eases hyperparathyroidism by carrying excess cal-cium back to our bones.

• By carrying excess phosphorus to bones together with cal-cium during the bone-building process, our body’s calcifi-cation factor is lowered, preventing further calcification.

MILD HYPERCALCEMIAHYPOCALCEMIA NORMAL 4.3-5.6

Amount of Ca2+ added by AIC 8mg/dL

6

TIME & WATER FOR PROPER AIC INTAKEAIC has to be mixed with room temperature or cold water at 1:100 ratio and taken in an empty stomach at least 2 hours after and 30 minutes before any food intake. More than 95% of AIC will be absorbed within 30 minutes through diffusion and osmotic pressure.

Most kinds of water can be used with AIC. Alkaline water, hydrogen water, filtered water, reverse-osmosis water, and mineral water all work well with AIC. Any additives such as other supplements or food substance that may interact with AIC should be avoided as AIC will interact and lose potency. Taking AIC without mixing it with water will render it useless as ionic calcium therapy, and no hot water above 55 °C should be used.

If taking AIC 4 times a day, the suggested schedule is: at 7 a.m., right after rising up, at 11 a.m., 30 min before lunch, at 5 p.m., 30 min before dinner, at 9 p.m., one hour before bed. Drinking much water may be difficult for some patients; however, drinking 2 L of water is recommended by many health experts.

7

AIC STORAGEAIC comes in colored glass bottles for a more extended preservation period. Unless it is not exposed to direct sunlight and stored below 55°C (131°F) unopened bottles of AIC will last more than ten years without losing potency. Once the bottle is opened, the product is to be consumed within six months without experiencing the loss of therapeutic potency.

As bottles are opened and closed, the air introduced can react slightly with AIC and cause minute precipita-tion of calcium carbonate, making the solution more cloudy, but it won’t affect efficacy much. The bottle cap should be tightly closed immediately after each dosing to minimize the exposure to air.

Once mixed with water, the solution should preferably be consumed within 10 minutes and not exceeding 30 minutes. If the solution is premixed in a tightly enclosed plastic container for later consumption, please make sure that the solution is not exposed to direct sunlight and consumed within 6 hours from the time of the mix. The container should not be too big to contain much air. However, for the best results, it is highly recommended that AIC is mixed fresh right before consumption.

No pathogens can survive in AIC solution due to the presence of a high concentration of ionic calcium.

8

AIC DOSAGE FOR PREVENTIVE HEALTH

To trigger physiological responses that turn on thyroid stimulating hormone (TSH), thyroid hormone (TH), and osteoblasts involved in the strong bone-building process, about 3 mg dose of AIC seems to be enough for typical healthy adults. Therefore, there is enough AIC in one dose of MegaGen (our maintenance product providing 5 mg of AIC in 5 ml solution) to help maintain good calcium homeostasis for healthy adults.

Bone health is a good indicator of overall health. By strengthening the bone turn-over process, AIC prevents age-related bone loss, which starts around the average age of 35. This natural bone loss, often exacerbated by poor diet, unhealthy life-style, hormonal imbalance, toxins, and poor gut health, lay a pathogenic pathway for many degenerative diseases.

One dose of MegGen a day, therefore, serves as proper maintenance and preven-tative dose for the healthy who wants to maintain good bone health, preferably after achieving a normal bone scan reading above - 1 (T-score).

9

AIC DOSAGE FOR DEGENERATIVE DISEASEChronically sick patients have much higher calcium needs due to the presence of an active disease momentum. In all cases, there is a profound ionic calcium deficiency and broken calcium homeostasis for unhealthy patients. Therefore, for such patients, more AIC is needed per dose and per day to address deep calcium needs and to counteract the disease momentum.

To bring in faster systemic change and to assure a better chance for recovery, a higher dosage from the beginning of the treatment is recommended. MaraGen, which provides 7.6mg of AIC in 5ml solution per dose, is prescribed for patients with sickness, often 2-4 times a day, depending on the severity of the disease. To maintain the effects of AIC for maximum efficacy, a patient can take AIC every three to four hours, up to six times a day, if practical.

Robust bone rebuilding process triggered by AIC helps to reverse calcification, to reverse mitochondrial dysfunction, to restore cellular signaling, and to reduce oxidative stress, thus alleviating inflammation and triggering health restoration. AIC also normalizes body pH to ideal 7.4 and also corrects and strengthens our immune system and trigger the reboot of cellular health to fight the disease. Patients with an advanced stage of the disease with other concurrent calcium-related diseases may take much longer to see the desired effects of AIC therapy, however.

10

AIC DOSAGE FOR CANCERMost cancer patients display low skeletal bone density and heavy calcification both in systemic and intracellular levels, which indicate severe calcium displacement caused by disturbed calcium homeostasis. Also, cancer patient’s low body pH caused by lactic acid production of cancer cells further indicates the deep need for ionic calcium as it plays a critical role in maintaining proper body pH and maximize oxygen supply.

Because cancer patient’s physiological need for ionic calcium is 2 to 5 times greater than healthy people, a minimum of 4 to ideal 5 to 6 doses of MaraGen is recom-mended for all stage cancer patients, thus arming the body to fight cancer. Good time to take AIC if taking four times a day is: at 7 a.m., right after rising up, at 11 a.m., 30 min before lunch, at 5 p.m., 30 min before dinner, at 9 p.m., one hour before bed.

AIC therapy is effective against cancer for the following changes to health outcomes: 1) Restores body to the ideal pH by neutralizing lactic acid and ammonia, which turns on the immune response around tumors and inhibits angiogenesis and maximizes oxygen supply 2) Restores the function of p53 gene and induce apoptosis 3) Inhibits inflammatory enzymes, such as COX-2, which spreads cancer 4) Restores mitochon-drial functions and builds a strong barrier of healthy cells around cancer 5) Reduces oxidative stress, systemic inflammation, and autoimmune responses, providing anti-cancer physiological environment.

11

AIC THERAPY FOR CANCERAIC therapy had many successes with all staged cancer patients, including the last stage with metastasis as a standalone therapy. However, for patients on other primary thera-pies, AIC therapy comes as an excellent adjunct and adjuvant therapy working synergis-tically alongside many alternative therapies. AIC therapy, however, is not very useful if administered alongside aggressive conventional cancer treatments.

Some patients respond very well to AIC therapy and may display improved blood works and heightened energy and activity levels. However, sometimes such rapid recovery may produce contradicting medical results such as enlarged tumor size and elevated cancer markers. In such cases, as long as the patient’s condition is better and all the blood works look promising, please do not stop AIC therapy just because of the larger tumor size and increased cancer markers.

Rapid apoptosis of cancer tumors may cause cancer to look more prominent in the scans and raise the cancer markers in the initial weeks to even alarming level. In many clinical cases, enlarged tumors collapsed, and cancer markers dropped as the patients’ condition continued to improve. Some tumors were left hollow with scar tissues and began to breakdown subsequently. Please follow the AIC therapy phase 1 to 3 for all cancer stages and monitor the progress carefully with care providing physicians.

12

AIC THERAPY PHASE ONEPhase 1: Remission Induction | Duration: Minimum 6 months

Many positive results or rapid recovery from symptoms may be experienced during Phase 1. Results may fluctuate for the first three months. If AIC therapy seems to be helping, continue to second 3-months. When the patients feel better, and symptoms disappear, do not stop or reduce the dosage of the protocol but remain at the proto-col’s max dosage.

At this phase, the improved condition is maintained only by the continued cellular influx of AIC. The purpose of Phase 1 is reversing the disease momentum and rebuild-ing systemic health.

There is a high chance of recurrence of disease (especially cancer) if AIC protocol stops here. Continue Phase 1 until full remission.

Adjuvant detox programs are recommended during Phase 1 based on the patient’s toxin profiling.

1

DISEASE AIC SUPPORT OWN HEALTH

PATIENT’S HEALTH CONDITION

13

2AIC THERAPY PHASE TWOPhase 2: Consolidation | Duration: 6-12 months

Phase 2 starts when symptoms have completely disappeared, and patients feel already recovered from the disease. If the purpose of Phase 1 is to turn the disease momentum around and rid of the disease symptoms, the purpose of Phase 2 is to give our body enough time to repair and boost systemic health to eliminate the chance of recurrence.

It took years for our overall health to fail, and therefore we must give our body time to rebuild it. Since bone health is closely related to cellular calcification and subsequent systemic damages, taking AIC therapy at full dose all the way until the bone density returns to the normal range is recommended. (preferably with T-score greater than -1)

AIC SUPPORT OWN HEALTH


14

AIC THERAPY PHASE THREEPhase 3: Maintenance | Duration: All the way

Phase 3 starts when the patient is fully recovered not just from disease symptoms but also systemic levels as well. Because of AIC therapy’s efficacy on a wide range of health spectrum, patients may end up having better health than even before the dis-ease symptoms first appeared. The purpose of Phase 3 is to maintain what has been achieved through Phase 2.

Calcification from bone loss, which leads to cellular dysfunction, is a natural process of aging; however, its most detrimental impact is the triggering of the onset of degener-ative diseases. AIC therapy’s maintenance program, Phase III, together with a healthy diet and lifestyle, can minimize further damage by diseases. 1-2 dose/day of AIC is recommended for recovered patients.

3

AIC OWN HEALTH


15

AIC CANCER THERAPY PHASES

CANCER DIAGNOSIS

DURING PHASE 1 | 4 doses/day



Undetectable Cancer Symptoms

Disease Momentum

Disease Momentum

Systemic Breakdown (Underlying

Cancer Causing

Conditions)

Cancer Symptoms

Stage 1-3

Stage 4

Systemic Recovery

Receding Cancer

Symptoms

Systemic Recovery

Systemic Maintenance

Acidic Body, Low Oxygen Delivery, Low Body Temperature, Inflammation,

Compromised Immune System

Intracellular Calcification, Calcium Signaling Breakdown, Mitochondrial Dysfunction,

Oxidative Stress

Even after successful conventional treatments with the absence of cancer symptoms, AIC therapy Phase I is recommended if the underlying cancer-causing systemic condition is not addressed. Some aggressive treatments may leave patient’s systemic health more damaged.

16

SAMPLE AIC DOSAGE PROTOCOLAll Stage Cancers:Please take AIC on an empty stomach at least 30 minutes before a meal. Take one dose after waking up, one at 30 minutes before lunch, one at 30 minutes before dinner, and one at 1 hour before bed.

Blood tests are recommended for every 2-4 weeks to monitor progress.

DXA/ultrasound bone scans are also recommended at the beginning of each phase to measure bone health progress. Reaching the minimum T score of -1.0 (normal) is recommended before moving unto Phase 3 if the patient started with low bone density.

Take 5ml of MaraGen in 500ml of water

4x daily

Phase I requires 15 bottles (250ml size)

PHASE I


3x daily

Phase II requires 11 bottles

PHASE II


2x daily

Phase III requires 8 bottles

PHASE III

Notes:

The number of bottles required is based on 250ml size. In the above estimate, Phases 1, 2, and 3 are estimated to be 6 months each. Please refer to cancer dosage protocol to manage expectations.

Post-Phase III Maintenance Dosage: 1x MaraGen daily after 3 years of no recurrence

17

SAMPLE AIC DOSAGE PROTOCOLNeuro-Degenerative Disease:For Parkinsons, MS, ALS: Use MaraGen | For Alzheimers: Use AlziGen.

Dual X-ray absorptometry (DXA) or ultrasound bone scans are also recommended at the beginning of each phase to measure bone health progress. Reaching the minimum T score of -1.0 (normal) is recom-mended before moving unto Phase 3 if the patient started with low bone density.

This dosage is also effective for epilepsy, arrythmia, Lyme disease, viral/bacterial infection, and metabolic syndrome.


3x daily

Phase I requires 11 bottles

PHASE I


2x daily


PHASE II


1x daily


PHASE III

Notes:

The number of bottles required is based on 250ml size. In the above estimate, Phases 1, 2, and 3 are estimated to be 6 months each.

Post-Phase III Maintenance Dosage: 1x MaraGen daily

18

SAMPLE AIC DOSAGE PROTOCOL


2x daily


Take 5ml of CartiGen in 500ml of water

1x daily


PHASE I


2x daily


PHASE II


1x daily


PHASE III

Post-Phase III Maintenance Dosage:

1x CartiGen daily

Arthritis:For Osteoarthritis & Rhematoid Arthritis

AIC is not recommended for bone-on-bone arthritis cases.


19

SAMPLE AIC DOSAGE PROTOCOLOsteoporosis:To benefit from AIC, patients must stop osteoporosis drugs and wait 3-6 months before taking AIC.

Cancer patient’s bone density will not rise much until remission happens first.



2x daily


PHASE I


1x daily


PHASE II

Take 5ml of MegaGen in 500ml of water

1x daily


PHASE III

Notes:

The number of bottles required is based on 250ml size. In the above estimates, Phases 1, 2, and 3 are estimated to be 6 months each. Above osteoporosis protocol is for patients without other calcium related diseases, but patients with calcium related diseases are to remain on the Phase 1 until T-score reaches -1.0 and stay on Phase II as maintenance dosage with 1x MaraGen daily.

Phase III Maintenance Dosage: If T score is below -1 at the end of Phase 2, staying on Phase 2 until the T score reaches -1.0 before moving unto Phase 3 is recommended.

20

SAMPLE AIC DOSAGE PROTOCOLDental Issues:Removal of infected tooth and toxic tooth by a qualified biological dentist is recommended.



2x daily


Take 5ml of DentiGen in 500ml of water

1x daily


PHASE I


2x daily


PHASE II


1x daily


PHASE III

Post-Phase III Maintenance Dosage:

1x DentiGen daily

21

SAMPLE AIC DOSAGE PROTOCOLAuto-Immune Disease:For Lupus, Crohn’s, Hoshimoto’s, Eczema, Celiac, Vitiligo, etc

Please take AIC on an empty stomach at least 30 minutes before a meal.

DXA/ultrasound bone scans are also recommended at the beginning of each phase to measure bone health progress. Reaching the minimum T score of -1 (normal) is recommended before moving unto Phase 3 if the patient started with low bone density.


2-3x daily


PHASE I


2x daily


PHASE II


1x daily


PHASE III

Notes:

The number of bottles required is based on 250ml size. In above estimates, Phases 1, 2, and 3 are estimated to be 6 months each. This dosage protocol is good for many chronic degenerative diseases and communicable diseases including viral and bacterial infections.

Post-Phase III Maintenance Dosage: 1x MaraGen daily

22

PHYSIOLOGICAL EFFECTS OF AICAfter intake, AIC’s effect lasts about four hours in our body, initially raising the serum ionic calcium concentration to a higher yet safe level to trigger various physiological functions before bringing down the serum ionic calcium concentration down to the average physio-logical level.

During the process, bone-building osteoblast with osteoclastic activity is triggered, and kidneys try to excrete excess ionic calcium through urination. The urge to urinate within an hour of taking AIC is both healthy and normal, indicating that AIC is working. However, when the patient is in deep need of ionic calcium, the urge to urinate is much less, indicat-ing ionic calcium deficiency.

As AIC initiates the bone-building process, protein-bound calcium in serum is also acti-vated, releasing both ionic calcium and protein, which is used for energy production. Ionic calcium aids cellular metabolism, releasing more ATP (adenosine triphosphate) and raising body temperature.

Thyroid Hormone Release

Reference safe elevated ionic calcium level

Reference normal ionic calcium level

(4.3~5.6 mg/dL)

Para Thyroid Hormone & PTHrP Hormone (Cancer Cell) Release

Chronic Calcium Ion Deficiency

Diffusion

Osteoblast

Excretion

Joints & Body

Bone

Urine

23

AIC OVERDOSEWith AIC therapy, generally, there is no overdosing problem. If a person drinks an entire bottle of AIC without mixing with the proper amount of water, AIC is just absorbed as regular calcium carbonate (180 mg of calcium as calcium carbonate in 120ml solution), and none is absorbed as ionic calcium.

If AIC is properly mixed in prescribed 500 ml of water, the amount of water will naturally limit overdosing. How much water can an average normal person drink to overdose on AIC?

If more AIC is added to the prescribed 500ml of water, its absorption rate will significantly decrease to limit the absorption of ionic calcium within the safe level. Excessive concentration of ionic calcium circulating in the blood, if happened, is excreted in the urine.

The only concern of overdosing is with the selenium amount as each AIC dose provides 80% (40mcg) of the required daily value. Over 300 mcg of selenium for an extended period of time may cause health issues. Taking MaraGen 6 doses a day remains well within the safe range of the selenium intake.

24

IMPROVED EFFICACY WITH INCREASED DOSAGEEfficacy of AIC therapy increases non-linearly with the number of doses. For instance, taking AIC twice a day has more than double the efficacy of taking AIC only once a day in our clinical experi-ences. It is comparable to two people carrying a table instead of just one. Two can handle the job much easier.

Therefore, by taking AIC many times a day, one can experience multiplied AIC efficacy compared to taking just one dose a day and able to curb the disease momentum and shorten the therapy duration, making AIC therapy more cost-effective as well.

There are no side effects of taking AIC multiple doses a day as our body is able to manage AIC-induced small fluctuations of plasma ionic calcium levels.

By taking multiple doses a day, AIC therapy has a better chance of combating the disease momen-tum and speeding up the recovery time. All treatments, therefore, should start out two to three doses a day, except cancer which requires minimum four a day.

12

9

6

3

0

1 Dose/Day 2 Dose/Day 3 Dose/Day 4 Dose/Day

Non-Linear Efficacy of AIC Linear Efficacy

25

STARTING WITH A STRONG DOSEA person does not go from being healthy to sickly overnight if not from injury or infec-tion. Therefore, when a patient is diagnosed with a degenerative disease, the deterio-rating condition has been around for a while, involving many other inter-related health issues, before the manifestation of evident symptoms. If nothing is done or changed, the diseased condition inevitably deteriorates with more significant momentum. To fight this gaining momentum, it is always better to fight back strong from the beginning of the treatment.

Patients with diseases, therefore, should start with MaraGen (our strongest AIC prod-uct) at least two to three doses a day for all conditions except cancer for which we recommend a minimum of 4 doses a day.

If a patient is relatively healthy and the condition is moderate, start with two doses of MaraGen a day; however, three doses of MaraGen a day are recommended for all con-ditions to stop the disease momentum from the get-go.

26

AIC IS A SYSTEMIC THERAPYAIC is not a targeted therapy that only focuses on the relief from the symptoms of the disease. Instead, AIC is a systemic therapy that focuses on treating the root causes of the disease from the cellular level. Therefore, it generally takes longer to clinically expe-rience the positive effects of AIC therapy compared to symptom-targeted treatments. However, once the dis-ease momentum is reversed, the recovery often accel-erates with results that are far better compared to the therapies that just focus on relief from symptoms.

Restoration of calcium homeostasis at cellular level restores mitochondrial functions, reduces oxidative stress, eases inflammations, and corrects cellular communication signaling errors. AIC therapy helps to prevent debilitative systemic issues and switch on our body’s strong healing abilities to combat the disease; however, both time and patience are required from patients. From healthy cells to healthy tissues to healthy organs to healthy systems, AIC helps to rebuild our body.

The anticipated rate of success of AIC therapy depends on several variables, including the patient’s medical history, ability to heal, and proper dosage strength, hence AIC products are not sold on shelves but dis-tributed only through practicing medical practitioners who could gauge and monitor patient’s variables while undergoing AIC therapy protocols.

27

CRITICAL 3-MONTH MINIMUM TREATMENTBecause of AIC’s workings at systemic levels, the health improvement expe-rienced may fluctuate for the first 3-month period of the treatment for most patients until these positive results start to dominates during the second 3-month period of therapy.

It is also during the first 3-month period of the treatment when healing reac-tions are experienced for some patients as our body tries to balance the heal-ing effects of AIC. Healings reactions from AIC tends to subside and disappear for most people during the second 3-months period of AIC therapy.

Therefore, it is advised that AIC treatment should be given at least for a mini-mum of 3-month of period to look for any positive results before committing another 3-month of AIC therapy. If any positive results are observed during the first 3-month period, then we recommend another 3-month period of therapy to be given to curb the disease momentum.

During these two 3-month periods, many patients experienced enough posi-tive effects of AIC therapy that encourages them to continue the treatment all the way to full recovery.

28

CRITICAL 3-MONTH PERIODS OF CASE STUDYIn the case of an 80-year old lady with last stage multiple myeloma, the road to her full recovery had mixed signals.

In the first 3-month of AIC therapy, there was a clear sign that the therapy was working, followed by a dip that seems to indicate that is was not. Because there were some good signs, the second 3-month of treatment were given, which also had ups and downs. However, during the second 3-month period of treatment, there were more positive effects, including her general feeling of wellbeing.

When Molly had committed to the third 3-month of treatment, her lab results and health steadily climbed up to full cancer remission. Her bone density returned to normal (-0.9) from osteoporosis (-3.4), and the kidney function bounced back up to GFR 60 from GFR 10.

2013 2014 2015 2017

WBC

(ml)

Hem

oglo

bin

(g/l)

Pla

tele

t (m

l) N

eutr

ophi

l (m

l)

180,000

160,000

140,000

120,000

100,000

80,000

60,000

40,000

20,000

5000

4500

3500

3000

2500

2000

1500

1000

500OCT 2013

NOV 2013

DEC 2013

JAN 2014

FEB 2014

MAR 2014

APRIL 2014

MAY 2014

JUNE 2014

AUG 2014

OCT 2014

DEC 2014

JAN 2015

MAY 2017

SEPT 2017

NOV 2017

PLATELETWHITE BLOOD CELL (WBC) NEUTROPHIL

DISCOURAGING MOMENTSSTART OF AIC TREATMENT FULL RECOVERY

1st 3-Month 2nd 3-Month 3rd 3-Month

Phase 2 Phase 3

Multiple Myeloma Case (80 F)

Phase 1 Phase 1 Phase 1

29

MOLLY’S SUCCESS STORYMolly started on AIC therapy when she stopped taking anticancer medication for her last stage multiple myeloma. (2012)

After taking MaraGen for ten months, her blood test results showed to be almost normal. Molly had other benefits from taking AIC treatment. Her rib fracture healed up quickly, her low kidney function improved significantly, and her thrombosis was lifted. Moreover, her low bone density increased to the normal range for her age. Molly’s oncologist declared her to be cancer free to this date. (2019)

30

HEALING REACTIONS, NOT SIDE EFFECTSWhen a patient is in a diseased state for a while, the body is in a physiological imbal-ance in many ways. Because AIC works at the systemic level by restoring proper cellular communications and rebuilding cellular functions, the body in response tries to regain balance again. Some of these reactions can feel painful and uncomfortable and thus called a ‘crisis’ at times.

Healing reactions/crisis should not be confused with side effects, which is caused by unwanted adverse effects of medications and is considered harmful. AIC has no known side effects nor contraindications with other supplements and drugs. (Any medicines that interact with ionic calcium cannot be approved as a safe drug by FDA in the first place.) AIC only increases the serum ionic calcium level by 2% per dose, which is well within the safe level.

Healing reactions/crisis of AIC therapy actually means that AIC is indeed working; how-ever, when the pain is too much for patients to bear, the dosage should be reduced, or the protocol should stop and try again at later times.

31

TYPES OF HEALING REACTIONS Because AIC therapy works at most basic and systemic levels to restore the balance destroyed by disease momentum, the healing process sometimes involves unwanted pains and discomforts. Some common healing reactions include minor headaches, upset stomach, constipation, diarrhea, light fever, aches in joints and muscles, skin rash, joint inflammations, fatigue, sleepiness, etc.

Patients respond differently based on their health conditions. For example, patients with heavy metal toxicity often experience skin rash as restored cells try to expel toxic metals such as lead and mercury. Patients with injuries may experience pains around old injuries. For other patients, it is the effects of rebalancing of hormones. Still, others are effects of restoring gut microbiome and gastrointestinal tract health.

Many patients do not experience any healing reactions, while others do experience it at varying degrees. Patients with advanced disease conditions with low bone density and heavy calcifications tend to experience more pains of healing crisis. For most people, these reactions are both light and short-lived, but for a small percentage of patients with substantial calcium problems (calcification) and toxin build-up, symptoms may last anywhere from weeks to months.

When the healing reaction is too strong to bear, patients are advised to reduce the dosage to the level where the healing reactions are manageable or to stop AIC therapy altogether and restart after several days of rest. Please start again at a lower dosage and increase to the recommended dosage as toleration builds up.

32

MINIMIZING HEALING PAINS• Proper nutrition is crucial for maintaining health as well as repairing

health. As AIC initiates a cascade of responses in our body to bring deep healing, proper nutrient, hydration, and detoxification is recommended to alleviate and remove healing pains as well as accelerating healing. When the body begins to process better metabolically, micronutrients are gobbled up at a very accelerated pace and needs to monitored and replaced as needed. Serum calcium levels may drop for some patients as calcium is better utilized.

• Magnesium oil can be applied to joint inflammation to ease the pain. Oral magnesium supplements also help. (200-500 mg)

• Vitamin D is not needed for AIC absorption; however, vitamin D is an important hormone that is needed for the proper functions of our body. Vitamin D level above 70 ng/ml is recommended while taking AIC, and preferrably above 100 ng/ml for cancer patients.

• Patients who do not experience good bone density increase undergoing AIC therapy may try taking iodine supplements. (5-10 mg a day accord-ing to the patient’s deficiency level)

• Patients who have been using steroids may experience inflammation as AIC therapy strengthens the activity of the immune system.

• Patients with low body temperature may experience body aches as the immune system is strengthened and the body tries to detox, bringing acidic pH to the ideal 7.4. Body temperature rise may accompany much sweating.

• As our GI tract gets healthier, detoxing may cause diarrhea, or more water absorption may cause constipation. Magnesium supplementation of 500mg a day helps relieving AIC-induced constipation.

33

CONTRAINDICATIONSAIC therapy provides what is already present plenty in our body: ionic calcium. An average adult has about 200mg of ionic calcium doing its work everywhere. Adding a tiny amount of ionic calcium to trigger and induce natural responses, therefore, has no side effects and contraindications with other supplements or drugs.

However, because osteoporosis drugs interfere with the natural bone turnover pro-cesses which AIC utilizes in building bones naturally, AIC works only when osteoporo-sis drugs are stopped and wears off. Please wait 3-6 months after stopping the drugs before AIC based bone-building starts.

If a patient is taking antibiotics, please space it with the intake of AIC for 2-3 hours.

If a patient is taking medicines for chronic conditions, please monitor drug dosage as patients’ condition improves (diabetes, hypertension, cardiovascular disease, etc.).

MINERAL INTERACTION:As calcium homeostasis is restored under AIC therapy, all other mineral functions in our body improve as ionic calcium plays a leading role. As naturally existing in our body, ionic cal-cium levels are precisely regulated and do not adversely react with other supplements and drugs.

34

COMMONLY TREATED CONDITIONS• Autoimmune disease (Lupus, Vitiligo,

Hashimoto’s, Crohn’s, Ciliac disease, eczema, MS, rheumatoid, etc)

• Lyme disease, HIV, MERs, shingles, Post polio syndrome, and other viral infections

• Parkinson’s, ALS, Alzheimer’s and other Neurodegenerative Diseases

• Arthritis, Gout, CPPD, Inflammations

• Mitochondrial Disease

• Cancer (carcinoma, sarcoma, lymphoma, leukemia, multiple myeloma, bone metastasis)

• Osteoporosis, Bone Necrosis, Fracture Healing, Thrombosis, Hemolytic Anemia

• Arrhythmia, Heart palpitation, Mitral valve prolapse

• Hyper & Hypo thyroidism, Hormonal Imbalance

• Diabetes, Metabolic Syndrome

• Glaucoma, Cataract, Intermittent Exotropia, Retinal Vein Occlusion

• Autism Spectrum Disorder, ADHD, Epilepsy

• Asthma, COPD

• Menier’s Disease, Vertigo, Aurora Migrain Disease, Tinnitus, Anemia

• Chromosome 8 syndrome

• Chronic Kidney Disease

• Gum disease, Loose teeth

• Calcium related Infertility, Dysmenorrhea, Irregular menstruation

• Calcification (joints and tissues), kidney stones, gallbladder stones, Fibrosis, Calcific tendonitis

• And many more. There are more than 150 cal-cium related diseases that causes secondary autoimmune and inflammatory responses.

35

DOSING FOR CHILDRENAll AIC products are formulated to 60kg (132lb) bodyweight. For children, the dosage and the water amount should be adjusted to the correct bodyweight, keeping AIC to water ratio to 1:100. For example, a child with 30kg of weight should take 2.5mg of MaraGen in 250ml of water as one dose instead of 5ml in 500ml as in adult dosage. Teens with adult weight (50 to 70kg/110-154lb) should go with adult dosage.

Osso Jr is formulated only for healthy kids to maximize growth potential and to help with mental sharpness. Any disease in kids, however, should be treated with MaraGen. MaraGen is safe even for babies and is to be administered through a baby bottle. (ex. 0.5ml AIC in 50ml of water for 6kg baby)

Osso Jr is recommended for ages up to 12, and kids approaching the size of an adult would benefit more from taking MegaGen instead.

36

DOSING FOR CKD PATIENTSFor patients with limited fluid intake such as Chronic Kidney Disease (CKD) patients (above GFR 10), 2-3 doses/day of MaraGen is recommended but with a reduced amount of water (350 ml to 400 ml) per dose, not exceeding the daily fluid intake limit set by the doctor. Absorption is compromised by 20-30% due to a lower AIC to water ratio (less than 1:100), depending on the stomach size and condition. However, it is better to take more doses of AIC than less.

AIC therapy does not put burdens on kidneys. However, for more severe patients who cannot drink much water at all, MaraGen IV treatment is recommended since it gives more potent AIC therapy with much less fluid intake.

(Please refer to MaraGen IV therapy)

37

MARAGEN IV INFUSIONFor patients with fluid intake limitations such as CKD patients, MaraGen comes in IV form, which can be infused in an intravenous drip. The difference between oral MaraGen and MaraGen IV is that there are no other substrates such as zinc, magne-sium, and selenium in Maragen IV. It is a transparent liquid with only AIC without other ingredients, as in the oral version of MaraGen.

Because of AIC’s weak sigma-antibonding, AIC entering the blood vessels disintegrates readily into ionic calcium, oxygen, and carbon dioxide due to 60 mV of weak electricity flowing in our body. Currently, MaraGen IV is shipped in the same 120ml container as oral MaraGen and not packaged in IV vials or ampoules.

During storage, MaraGen IV may build precipitation (calcium carbonate), which shows as suspended solids when the bottle is shaken. Drawing out a dose of AIC, a syringe with a syringe filter (0.22 um) attached should be used to filter out precipitates that may irritate veins.

2Ca2+CO3 2Ca2+ + O2 + 2CO2*Ksp = 7.5 x 10-7 to 8.7 x 10-7 at 25 0C

CaCO3 Ca2+ + CO32-

*Ksp = 3.7 x 10-9 to 8.7 x 10-9 at 25 0C

AIC CALCIUM CARBONATE

REGULAR CALCIUM CARBONATE

(BREAKS DOWN TO SAFE COMPONENTS)

* Equilibrium Constant

38

MARAGEN IV vs. ORAL MARAGEN5-10 ml of MaraGen IV is mixed into 250 ml of either sterile or 0.9% saline solution bag and dripped for about an hour. Other common IV infusions such as high dose vitamin C, magnesium chloride, curcumin, etc. can be mixed in and infused together without any contraindications. Because AIC is infused directly into our system, MaraGen IV circumvents the absorption challenges of oral MaraGen through the stomach lining (mucosa), and thus a stronger dose of AIC can be given safely.

When 10 ml of AIC solution is given, up to 15.2 mg of ionic calcium is introduced in our body, and the efficacy is raised significantly higher for patients who may have more significant calcium needs. Such a high dose is, however, not necessary for patients with low calcium needs because our body can utilize only so much ionic calcium, and the access is excreted to bring the ionic calcium level back to the average level within approximately 4 hour-period.

There is no issue with contaminations since AIC is sterile, just like alcohol, and no pathogens can survive in it. MaraGen IV should be administered only in countries where intravenous treatment is legal and only by licensed practitioners.

39

MARAGEN IV DOSING PROTOCOLForm & Ingredients:

Liquid in 120ml bottle similar to oral MaraGen. Identified by a blue dot in the packaging.

Maragen IV contains only AIC calcium carbonate, with-out selenium, zinc, and magnesium.

Usage:

Open and close the bottle as quickly as possible to minimize CaCO3 formation from AIC. Need to be filtered with syringe filter (0.22um, hydrophilic) when introducing to an IV solution bag. AIC can be admin-istered up to 10 ml in 250 ml saline or sterile solution and dripped for an hour. CKD patients can use a 100ml solution dripped for an hour. Minimum two IV sessions per day with 4-6 hours apart for most cancer patients are recommended. Adding oral intakes of one or two doses of oral MaraGen will increase the efficacy significantly. Syringe filter (22 um, hydrophilic) should be used to filter out precipitated calcium carbonate as it could irritate the vein. Precipitation is normal and does not indicate reduced potency.

Procedure:

1. Open the bottle and draw out AIC with a syringe which has a syringe-filter attached to filter out larger particles. The filter need not be sterile pack-aged as AIC is sterile. Close the bottle tight right away.

2. Remove the filter and inject it into an IV bag and drip for one hour.

40

NEBULIZING MARAGEN AIC can also be inhaled through a nebulizer. AIC’s property is still intact, and about 15-20% of a dose of AIC (5 ml) can be absorbed through the linings of the nasal cavity and lungs. Nebulizing is only recommended for supplementing either oral or IV AIC pro-tocol for the diseases that can benefit further from nebulizing, such as tumors or cysts in the nasal cavity, lungs, or ear canal where the absorption of AIC can directly affect the disease. Nebulizing can help many lung-related problems such as COPD, bronchitis, pneumonia, asthma, and cystic fibrosis.

However, nebulizing alone will not be enough for the treatment, but oral or IV AIC treat-ment should be considered as primary. Pneumonia should be treated together with antibiotics. A portable nebulizer is recommended for convenience.

Nebulizing Dosage

Recommended one dosage: 5 ml of MaraGen in 50ml of water. MaraGen to water ratio is 1:10. For nebulizing, either Maragen IV or oral Maragen can be used. Any water suit-able for oral intake can be used for nebulizing. Do not use a saline solution.

A portable nebulizer only holds 10-20ml of solution at a time. Use a bigger machine or do multiple times to nebulize all 50ml per session. At least two sessions a day are recommended for severe conditions.

41

MARAGEN VS MEGAGENThe information present in this section helps with understanding the differences in AIC content in Pronuvia products. By comparing MaraGen (the most robust AIC product) and MegaGen (maintenance product), we gain a deeper understanding of how AIC is absorbed in our body.

Absorption Rate & Effectiveness

MaraGen has 99% AIC purity and has 8.0 mg of AIC in 5 ml AIC solution

MegaGen has 90% AIC purity and has 5.0 mg of AIC in 5 ml AIC solution

Oral Intake is limited by the patient’s ability to drink 500 ml of water at a time. 500 ml of water expands our stomach for optimum absorption by diffusion and osmotic pressure.

AIC products are formulated to deliver the ideal amount of AIC for each product formu-lation at 5 ml of solution mixed into 500 ml of water at a 1:100 ratio. This means that the higher AIC solution to water ratio by putting more AIC into 500ml water will only reduce the absorption rate, and any unabsorbed AIC will be absorbed as protein-bound calcium in the duodenum by binding to vitamin D and not absorbed as ionic calcium.

42

MARAGEN VS MEGAGEN (CON’D)Example of oral intake of AIC

For example, 10 ml AIC in 500ml of water has a lower absorption rate, about 70% compared to 5 ml of AIC in 500 ml of water.

• MaraGen has 7.9 mg AIC absorbed at 5 ml in 500ml

• MaraGen has 10.5 mg AIC absorbed at 10 ml in 500ml

• MegaGen has 4.5 mg AIC absorbed at 5 ml in 500ml

• MegaGen has 6.3 mg AIC absorbed at 10 ml in 500ml

When we compare 10 ml MegaGen in 500ml of water to 5 ml MaraGen in 500 ml of water, Maragen 5ml actually delivers a greater amount of AIC in our body than 10 ml of MegaGen, delivering more physiological effect even at half the amount of MegaGen.

Absorption Rate of MaraGen vs MegaGen:

12

10

8

6

4

2

0

11.2

Abs

orpe

d Ca

lciu

m (m

g)

7.9

4.5

6.3

Mar

aGen

(5m

l)

Mar

aGen

(10m

l)

Meg

aGen

(10m

l)

1:100 Mixture Ratio 1:50 Mixture Ratio

Meg

aGen

(5m

l)

43

MARAGEN VS MEGAGEN (VERDICT) For most patients, MaraGen 5 ml (8 mg of AIC) will maximize the physiological ionic calcium benefits of the physiological moment, and the access will be excreted, bring-ing down the serum ionic calcium level to the reference level within 4 hours. For these patients, repeating the dosage every 3-4 hours will maximize the efficacy of AIC.

However, there are patients needing more ionic calcium where one dose of MaraGen (8 mg of AIC) is insufficient, and for such seriously ill patients, the following is recommended.

1. Maragen IV which delivers 16.0 mg of AIC per session. (10 ml in 250 ml IV solution)

2. 10 ml of oral MaraGen mixed to 500ml of water, which delivers 11.2 mg of AIC at 30% loss of absorption rate but still provides a much stronger impact than 5 ml dosage, which provides 8.0 mg.

We have seen patients with big ionic calcium needs recovering with multiple doses of standard 5 ml dose of MaraGen. However, 10 ml of oral MaraGen can give that extra push. (Cost will be higher)

MaraGen is the default AIC product prescribed for all sicknesses. MegaGen is for healthy people to maintain calcium homeostasis for the prevention of diseases and the protection of overall health.

44

RECOMMENDED BONE TESTS FOR AIC THERAPYThe conventional bone density test, known as the DXA or DEXA Bone Density Test can be done to test the bone density increase under AIC Therapy. For patients who do not want radiation exposure, there are other bone biomarker tests available: NTx and CTx. Also, bone density as measured by DXA provides a static snapshot of bones and does not distinguish if bone loss is ongoing or not. NTx and CTx, however, are dynamic mea-surements of what is actually happening in bone at any given time.

The urine NTx (N-telopeptide) Bone Test is inexpensive and non-invasive, making it easier to perform more frequently than the DEXA bone density test, providing increased insight into the true state of bone health and increasing chances of an accu-rate osteoporosis or osteopenia diagnosis. A baseline urine NTx value greater than 38 indicates significantly increased risk for decreased bone mineral density after one year. As the baseline NTx goes up from 38, the probability of a decrease in bone mineral den-sity increases significantly. For women being treated for osteoporosis, the probability that treatment is effective after three months is significantly increased if the NTx falls below 38 or drops by 30 percent from its baseline.

For a serum CTx (C-telopeptide) test, the normal range for women aged 18-49 ranges from 40-650 pg/ml. For patients being treated for osteoporosis, a serum CTx decrease of at least 25% from baseline 3 months after the start of AIC therapy indicates the ther-apy is working.

The main reason the serum CTx test is being recommended over the other bone resorption markers is that not all markers respond by the same amount for a given degree of bone resorption; for instance serum CTx tends to change more than urine NTx. Nevertheless, both are useful and currently in use.

The best way to take advantage of a urine NTx or serum CTx test is to find out your initial level of bone resorption and then plan to re-test about three months later using the same test at the same laboratory.

45

• w

INTRODUCTION TO NEW CALCIUM CARBONATEAntiorbital Ionic Calcium (AIC-CaCO3) as an adjuvant or an adjunct treatment.AIC is the world’s first calcium-ion-delivery-system that safely and ef-fectively achieves the threshold level of plasma ionic calcium concen-tration to initiate a cascade of hormonal responses that awakens our body’s amazing healing mechanisms!

46

EXPERTISE OF PRONUVIA -CBHI TEAMThe R&D Team of CBHI, a research institute based in Canada, invented AIC Therapy and continues the research to find more Health applications for AIC.

Pronuvia markets innovative AIC (Antiorbital Ionic Cal-cium) products to patients exclusively through doc-tors, health practitioners, and clinics around the world.

Paul K. Lee Chemistry, Ph.D

Martin Chun Material, Ph.D

O.S. Lee Foods Science, Ph.D

Edward Lee Materials Eng., Ph.D

James Lee Toxicology, Ph.D

W. S. Kim Material, Ph.D

Chris. Choe Energy, Ph.D

47

PRONUVIA SUCCESS STORY Currently, in the medical world, there is no effective way to prevent age-related bone loss and the resulting cellular calcification issues that serve as a trigger for hosts of degenerative diseases. Pronuvia’s innovative AIC therapy utilizes ionic calcium as a signaling agent to trigger our body’s self-healing responses to reverse calcification, causing domino effects of healing processes to rebuild our health on a systemic level.

Joining hands with many healthcare practitioners and clinics around the world, the Pronuvia-CBHI team expands the application of AIC in treating many difficult diseases. In-vited to speak in many health and medical conferences around the world, Pronuvia engag-es and partners with experts in the field to collaborate in new research, bringing hopes of restored health to desperate patients.

48

CBHI RESEARCH PARTNER ORGANIZATIONS

The Calcium and Bone Health Institute of Canada (CBHI Canada) is a scien-tific research-based institution founded in 2001 by Dr. Paul Lee that focuses on the role of calcium and its effect on our bodies.

CBHI collaborates with many reputed researchers from many different disciplines from SFU, UBC, UC Davis, NSERC Canada, and BC Government (BCBN). CBHI also works with many applied science faculties, such as engineering and computing science, to enhance the depth of the research.

CBHI is among the few Canadian research-based institutes that have been founded to study calcium-related chronic diseases, such as cancer, osteoporosis, Alzheimer’s, and others. The partnership with Pronuvia has helped over 100,000 people to experience the efficacy of AIC-applied ionic calcium therapy through participating physicians and clinics worldwide.

49

PROMISING ANIMAL OSTEOPOROSIS & CANCER TRIALS 2011 Osteoporosis animal trial proved to be very promising. In the bone break test, AIC built much stron-ger bones than other groups given regular calcium supplements. Also, rapid bone loss of osteopo-rosis-induced ovariectomized rats was fully recovered (100%) with AIC. The levels of osteocalcin, estradiol, and eosinophil increased significantly as well.

2017 Colorectal cancer animal xenograft trial also proved to be promising. Evaluation of AIC for tumor growth inhibition showed that 70% of tumors stopped growing or decreased in size within 3 weeks of taking AIC. (By Charles River, experiment number: Colo205-e347

BONE STRENGTH TRIAL

Dose Concentration BMD

AIC Calcium 0.0001% 102.2

Regular Calcium 0.01% 96.2

(AIC shows 100x effectiveness in bone strengthening power. 1ppm daily for 9 weeks)

OSTEOPOROSIS RECOVERY TRIAL (BMD)

Control placebo 0.2276

OVX (osteoporosis) placebo 0.1965

OVX + AIC AIC 0.2276

(AIC restores bone density fully to normal level from osteoporosis)

50

LACTIC ACID REDUCTION CLINICAL CASESLactic acid, which is the byproduct of carcinoma cancer cells, is known to inhib-it the immune functions around cancer tumors. Neutralizing the lactic acid and bringing pH back to a normal level is crucial in cancer treatment.

Twenty swimmers from Korea University swim team taking two doses a day for 14 days proved that AIC neutralizes lactic acid effectively. They all broke their records as a result.

28.50

28.00

27.50

27.00

26.50

2 3 4 5 6

Swim Trails

Swim

Rec

ord

(Sec

onds

)

9.50

9.00

8.50

8.00

7.50

7.00

6.50

2 3 4 5 6

Lact

ate

leve

l (m

mol

/l)

Swimming Records

Plasma Lactic Acid Level

Before

Before

After

After

Swim Trails

51

PROMISING HUMAN BONE HEALTH CLINICAL CASESCalcium and Bone Health Institute in Canada (CBHI) compiled the data of pre and post AIC therapy bone density measurements of hundreds of participating patients and found that over 90% of patients experienced noticeable bone growth with the majority achieving an unprecedented rate of growth unseen under any other treatments currently available.

•

52

•

FUNCTIONS OF CALCIUM IN THE BODY• Muscle and Heart Contraction

• Bone and Teeth / Blood Clotting

• Stem Cell Regulation

• Neuro Transmitter / Second Messenger

• Hormone secretion / Enzyme Activation

• Immune system / Cell Membrane Stability

• Cell Functions and DNA Replication

Because of calcium’s role in cellular communications, precise regulation of its concentration is required for proper physiological functions of all systems of our body. Once the balance is tipped, the disease is inevi-table.

53

ONLY AIC PROVIDES CALCIUM IN IONIC FORMOur blood has 50% of serum calcium already in ionic form, and increasing it by 1-1.5% by AIC triggers the bone formation process (osteo-blast) and restores calcium homeostasis.

Ionic calcium (Ca2+) is the only physiologically active form that can trigger such processes for therapeutic purposes. As protein calcium from out diet is not well utilized with aging, our bones are broken down to provide needed ionic calcium. AIC can prevent such ionic calcium deficiency.

50%Ca2+

45%Protein Calcium

5%Inorganic Calcium

CALCIUM CONTENT

IN NORMAL BLOOD

54

AIC UTILIZES SIGMA ANTI-BONDING Sigma Anti-bonding is a very weak and unstable chemical bonding that rarely exists nat-urally at room temperature. They are formed when atomic orbitals combine in ways that lead to predominantly destructive interference. CBHI’s ten years of R&D made this possible for calcium carbonate. AIC is 200x more soluble and is the first calcium-ion-delivery-system to safely elevate the amount of serum ionic calcium level to initiate a cascade of hormonal responses, including osteoblast in building healthy bone.

Strong bonding and no net electrical charge

Electrical Charge

Weak Anti-Bonding

AIC CALCIUM CARBONATE REGULAR CALCIUM CARBONATE

UNIQUE PHYSICAL PROPERTY OF AIC

AIC molecules have active hydrogen bonds due to +2 charges and fly out together with water molecules to crystallize with CO2 in the air.

55

AIC EASILY RELEASES CALCIUM IONSANTIORBITAL IONIC CALCIUM (AIC-CaCO3)

AIC is 200x more soluble in water and 3x more reactive in chemical reactions due to it’s weak Sigma anti-bonding. Calcium ions are easily released due to weak bonding.

AIC

56

AIC IS ABSORBED BY DIFFUSION & OSMOTIC PRESSURE (Direct absorption with water. No vitamin D3 and peptides required)

57

ACTIVE VS. PASSIVE ABSORPTIONAIC’s Unique Passive Absorption

Stomach Digestion Needed Peptides & Vit D3 Required

Protein Calcium Inactive Calcium

Ca-P Ca

ACTIVE TRANSPORT (CALCIUM FROM DIET & SUPPLEMENTS)

Notes:

Side effects of inactive calcium include kidney stones, blood vessel calcification, stroke, heart attack, etc. Active Transport applies to calcium from both diet and calcium supplements such as calcium carbonate, calcium citrate, calcium lactate, calcium aspartate anhydrous, calcium orotate, calcium citrate malate, calcium gluconate, coral calcium, etc. Only AIC provides enough ionic calcium that is immediately utilized to activate inactive calcium to aid with bone and dental health, hormone regu-lation, mineral absorption, maintain ideal body pH, and restore calcium homeostasis.

Ca2+Ca2+Ca2+

Stomach No Digestion Needed Absorbed via Diffusion

& Osmotic Pressure

Ionic Calcium Activate Inactive Protein Calcium

Ca2+

PASSIVE TRANSPORT (ONLY AIC)

Ca2+

58

SAMPLE CLINICAL CASES ACHIEVED WITH AIC THERAPYFrom osteoporosis to Alzheimer’s and to cancer, AIC therapy pro-duced amazing results through a wide spectrum of multi-factorial degenerative diseases.

59

WHAT DO OUR PATIENTS SAY?

AIC therapy is helping my daughter’s Crohn’s disease!JOANNE B. - Age 66, Female, Canada

AIC therapy cured my friend of multiple myeloma.MOLLY HOLT - Age 80, Female, South Korea

I recovered from deadly heart condition! Pronuvia gave me new life!E. BARAGOOSH, - Age 59, Male, Canada

My blood sugar level dropped by 50 points!Y. S. KWAK - Age 69, Female, NYC

Arthritis pain and swelling is gone! Amazing!M. KIM – Age 53, Female

My bone density is normal. No more osteoporosis!M. S. PARK – Age 55, Male

60

Calcium Deposits

Calcium Deposits Disappeared

DE-CALCIFICATION EFFECTS OF AIC(Calcific Tendonitis Case)

In many clinical cases, decalcification happened in organs, soft tissues, bones, joints, blood vessels, and even in cellular spaces, which helped to stabilize calcium homeostasis. AIC carries displaced calcium back to where it belongs in building stronger bones.

61

FRACTURE HEALING EFFECTS OF AICSteroid Induced Osteoporosis, auto fracture (Male, 52, Indonesia)Dosage : MaraGen 2x /day for first 2 months and then only 1x. Able to walk normally again.

March 7, 2018 July 27, 2018 Dec 31, 2018

In dental applications, AIC effectively triggers hPDLCs (human periodontal ligament cells) to build stronger alveolar bones on both mandible and maxilla. After cleaning, cavitations resulted from extracted teeth were filled up with natural bone adequately without bone grafts, and implants showed tighter osseointegration as well as stronger bony support.

62

SAMPLE CLINICAL BONE DENSITY INCREASE

Age (Years)

3

2

1

0

-1

-2

-3

-4

-5

4482

4380

4278

4176

4074

3972

3870

3768

3666

3564

20 30 40 50 60 70 80 90

T-Sc

ore

Spee

d of

Sou

nds

(ms)

04/22/2015 (After)*

Age: 67 | T- Score: -0.3 | Z-Score: 0.6 | SOS: 4107

12/30/2014 (Before)

Age: 66 | T- Score: -1.7 | Z-Score: 0.8 | SOS: 3947

AGE: 66M T-Score Increase: 1.4 From osteopenia to normal in 4 months.

Before After

Osteoporosis

Osteopenia

Normal

04/22/2015 (After)

Age: 63 | T- Score: -2.7 | Z-Score: -0.7 | SOS: 3877

01/23/2015 (Before)

Age: 62| T- Score: -3.9 | Z-Score: -1.9 | SOS: 3740

AGE: 62F T-Score Increase: 1.2 From severe osteoporosis to osteopenia in 3 months.

Age (Years)

3

2

1

0

-1

-2

-3

-4

-5

20 30 40 50 60 70 80 90

T-Sc

ore

Spee

d of

Sou

nds

(ms)

Before After

Osteoporosis

Osteopenia

Normal

4530

4429

4328

4227

4126

4025

3924

3823

3722

3621

*CBHI utilized FDA approved ultrasound bone densitometer by BeamMed in measuring and comparing BMD data of more than a thousand patients. Over 90% of the patients experienced increased bone density.

63

TECHNICAL EXPLANATIONS FOUND IN THIS BOOK

FIND IT ON AMAZON, or visit

AICCALCIUM.COM

“CBHI believes that if the healthy calcium level within all of our cells is well main-tained, we will be free from hosts of debil-itating diseases. I hope AIC calcium brings renewed hope for many who are suffering and would like to thank all the members of the CBHI Canada research team who con-tributed to the publishing of this book.”

Paul K. Lee, Ph. D.

64

CLINICAL TRIAL SAMPLECANCER REMISSION UNDER AIC THERAPY

Ms. M. Holt (Age 80)Diagnosed with Multiple Myeloma (2012)

MRS. HOLT’S AIC THERAPY RESULTS:

• AIC Therapy began Dec. 2013

• Ms. Holt’s hematological data such as Platelet, WBC, and Neutrophil have normalized and declared cancer free.

• Ms. Holt’s chemo damaged kidney function has recovered. (GFR 12 to 62)

• Ms. Holt’s BMD score also has significantly improved after treating with AIC, fully recovering from osteoporosis.

65

Date White Blood Cell (WBC) Hemoglobin Platelet Neutrophil

10/25/2013 2,590 10.1 79,000 1,350

11/27/2013 2,190 9.4 35,000 890

12/27/2013 3,150 9.9 62,000 1,560

1/21/2014 3,650 10.9 89,000 1,710

2/18/2014 3,370 11.3 55,000 1,540

3/18/2014 3,260 10.8 55,000 1,670

4/8/2014 2,670 10.0 67,000 1,270

5/13/2014 3,520 9.9 89,000 1,760

6/17/2014 3,190 10.0 90,000 1,400

8/5/2014 4,160 11.5 101,000 2,160

10/7/2014 4,300 10.5 114,000 2,230

12/9/2014 4,700 11.2 145,000 2,290

1/27/2015 4,760 11.4 152,000 2,560

Normal Range 4,000~ 10,800/mlM: 13~17g/dllF:12!~16g/dll

150,000~ 400,000/ml

2,000~ 7,000/ml

MRS. HOLT’S BLOOD TEST RESULTS

66

160,000

120,000

80,000

40,000

0

10/25/2013 1/21/2014 4/8/2014 8/5/2014 1/27/2015

PLATELET INCREASE | NORMAL RANGE: 150,000~400,000/ML

NORMAL RANGE

5000

3750

2500

1250

0

10/25/2013 1/21/2014 4/8/2014 8/5/2014 1/27/2015

WHITE BLOOD CELL INCREASE | NORMAL RANGE: 4000~10,000/ML

NORMAL RANGE

67

2600

1950

1300

600

0

10/25/2013 1/21/2014 4/8/2014 8/5/2014 1/27/2015

NEUTROPHIL INCREASE | NORMAL RANGE: 2000~7000/ML

NORMAL RANGE

BONE DENSITY & GFR INCREASE | T SCORE NORMAL RANGE: Above -1.0

Date T Score GFR

Nov 25, 2015 -0.9 62

Nov 20, 2015 -3.6 12

68


Mr. J Crook (Age 66)Diagnosed with Prostate Cancer with Liver Metastasis (2018)

69

MR. J. CROOK’S DIAGNOSIS(JUNE 18, 2018)Exam Type:

CT Chest

History:

Pleuritic Chest Pain, Query Metastatic Disease

Technique:

Unenhanced Volumetric Axial Images were obtained through the Chest with Standard Reformats

Findings:

There are several enlarged left supraclavicular lymph nodes, with the largest measuring 1.7cm in size.

There are is fairly extensive coronary artery calcifications.

The visualized upper abdomen re-demonstrates numerous masses throughout the liver. Re-demonstration of multiple enlarged upper abdominal lymph nodes.

Impression:

1. Left supraclavicular lymphadenopathy, favoured to be metastatic in nature.

2. No other findings of intrathoracic metastatic disease.

70

MR. J. CROOK’S POST AIC RESULTS(OCTOBER 26, 2018)Exam Type:

CT Abdomen and Pelvis Enhanced

History:

Known Prostate Cancer with Visceral Metastases

Technique:

Enhanced CT of the abdomen and pelvis with intravenous contrast

Findings:

After taking AIC since July:

The segment 4a lesion has decreased to 1.6 cm from 3.3 cm. Most of the other lesions have also decreased in size. No definite new lesions in the liver. The prostate gland has decreased in size with no new focal lesions.

Multiple lower retroperitoneal and iliac chain lymph nodes have decreased in size. A lymph node just inferior to the aortic bifurcation has decreased to 10 mm from 23 mm. No definite new lymphadenopathy.

6/1 6/18 7/18 8/14 9/13 10/9

PSA 26.0 ug/L 46.0 ug/L 6.27 ug/L 2.62 ug/L 1.70 ug/L 0.99 ug/L

*Reference Range of PSA: 0-4.50 ug/L

• No concurrent conventional treatments done with AIC therapy

• AIC therapy is given from the first week of July, 2018

• Dosage: 5ml Maragen in 500ml water / 3 ~ 4 times a day

71


Ms. Jin (Age 59)Diagnosed with 4th Stage Ovary Cancer (2019)

72

MS. JIN’S PROGRESS REPORTTREATMENTS RECEIVED:December, 2018

Oophorectomy performed

October, 2019

Chemo and radiation treatment stopped as Ca125 rose above 10,000 and cancer contin-ued to spread all over the body.

October, 2019

Maragen IV treatment started with 10ml of Maragen in 250ml 0.9 saline solution 2x/day.No other therapies administered.

Anecdotal improvements experienced within 2 months of AIC therapy:• Stomach much more comfortable with increased appetite and more nutritional absorption.

• No longer needs sleeping pills to fall asleep

• Every morning trip to bathroom now possible. Difficulty of urination and pooping alleviated.

• Emotionally brighter and her face looks lively. Started gardening and house works again.

CA125 Measurements under Maragen IV:

10,000

7500

5000

2500

0

09/29 10/16 10/24 10/31 11/7 11/14

( U/m

l )

73

AIC THERAPY PRODUCT LINE UPNPN 80043292 - CANADA

74

MARAGENFORMULA FOR CANCER AND INCURABLE DISEASEMaraGen is Pronuvia’s most robust AIC-applied product, which aims to rebuild degener-ated systemic health from the cellular level. By promoting decalcification from cellular to systemic level by stimulating osteoblasts, MaraGen helps to recover from over 150 degenerative diseases that are thought to be calcium-related. Many studies link cellular calcification to mitochondrial disease, metabolic syndrome, neurodegenerative dis-eases, and even cancer.

According to Mitochondrial Free Radical Theory, calcium ions accumulated in the walls of mitochondria induces production of reactive oxygen species (ROS), which damages DNA, RNA, and proteins, and thus becomes the leading cause of both aging and cancer. By triggering calcium homeostasis, MaraGen can reduce the production of ROS, restore cellular signaling, repair mitochondria dysfunction, build a strong immune system, and promote stem cell activities.

Pathogens and cancer cells thrive in an acidic environment due to the lack of oxygen in the body. When the blood pH is restored to ideal 7.4, our immune system is optimized to detect and destroy pathogens and reduce inflammation. MaraGen helps our body to neutralize the acid and restore the ideal body pH.

A GOLF BALL SIZED TUMOR - GONE!

I am a US Air Force pilot and one day was diagnosed with a brain tumor the size of a golf ball. I was dev-astated. However, when I heard about AIC therapy, I participated in it for three months before I got another brain scan at the Washington Bethesda Medical Center. The doctor asked me incredulously,”How come I do not see the tumor?”

MaraGen is a miracle supplement!

Merry - Female, 30.

75

MEGAGENFORMULA FOR OSTEOPOROSIS AND BONE HEALTHOsteoporosis and hormonal imbalances start affecting many people in their middle ages. Utilizing revolutionary AIC technology that delivers ionic calcium directly to our blood plasma, MegaGen is formulated to trigger our body’s natural responses to balance our hormones and initiate the cascade of repairing processes with manifold health benefits including maintaining healthier bones to prevent osteoporosis.

The most noticeable result is strengthening of our bones by stabilizing calcium homeo-stasis. It is formulated to be a maintenance product for healthy individuals who want to fight aging-related bone loss and subsequent disruption of calcium homeostasis, which ultimately leads to hosts of degenerative diseases. MegaGen is truly a champion in main-taining optimum health, considering its manifold health effect.

Even as an antioxidant, MegaGen is unmatched in its potency and effectiveness com-pared to other products at a matching price range. MegaGen does what MaraGen can at maintenance strength. Benefits of MegaGen are too many to list.

IMPROVEMENTS WITH SLEEP, KNEE PAIN & DIABETES

I decided to try MegaGen to lower my blood sugar level. From the very beginning of taking it, my level dropped by 20 mg/dL and leveled out. I was excited and wanted more benefits, but I also knew I had to exercise and stop drinking. Then I noticed that I was sleeping much deeper and woke up more refreshed without waking up in the middle of the night. Also, I noticed that my left knee, which bothered me so that I had to hold handrails and take a few steps between rests, sud-denly felt much better. The benefits I experienced from AIC therapy surpassed anything I tried at any cost! And I tried it for one month only!

S. L. – Female, 40, Indonesia

76

CARTIGENFORMULA FOR ARTHRITIS AND JOINT HEALTHLife takes a toll on our bones and joints. With age comes painful joints caused by wear and tear of cartilage and bones, and unfortunately, modern medical science only pro-vides solutions that may ease pains and inflammations with many side effects. Also, because there are no blood vessels delivering nourishment to joints readily, the natural healing process of joints is too slow for most patients to overcome daily damage.

Ionic calcium moves freely in and out of blood vessels to reach the joint matrix and initiate cartilage repair by stimulating stem cells in the cartilage, namely chondrocytes. Also, anti-inflammatory and immune-normalizing effects of ionic calcium offer a scien-tifically superior solution for easing joint disorder pains. Formulated for cartilage repair, CartiGen helps more ionic calcium to permeate deeper into the joints to help rebuild damaged cartilage (stem cell action) and by removing painful mineral deposits. (calcium homeostasis)

For faster results, MaraGen can be taken together with CartiGen.

10 YEARS OF ARTHRITIS PAIN NOW SUBSIDING

I was hit with rheumatoid arthritis about 10 years ago. To escape stiffness and pain, I tried everything. My fingers were bent and knee pain was unbearable. My toes also hurt so much that I could not walk properly. Numerous doctor visits gave me different diagnosis such as virus, genetics, etc., which did not help me at all. On February 8, 2017, my friend introduced my to AIC therapy. After taking it for two weeks, the pain subsided dramatically, and now I can walk normally with my toe touching the ground! Two weeks of CartiGen is taking care of my 10-year-old problem!

Jung C. – Female, 66, Canada

77

ALZIGENFORMULA FOR BRAIN HEALTHThe global cost of Alzheimer’s disease (AD) and dementia is estimated to be $605 billion. However, there are no drug treatments available that can provide a cure for Alzheimer’s disease yet. Many health professionals label AD as type 3 diabetes, and others suggest age, genetics, and mineral imbalances as the possible cause of AD.

New research has linked the onset of Alzheimer’s disease to disturbance of calcium homeostasis in the brain cells, which alters calcium signaling pathways that account for at least three major and interrelated toxic pathways: oxidative stress, mitochondrial dysfunction, and neuroinflammation in neurodegenerative diseases.

The aging-associated progressive loss of bone mass is largely to blame for this dis-turbance of calcium homeostasis, which in turn leads to neurodegenerative diseases. According to recent scientific research, senior women who have low bone density are more than twice likely to develop Alzheimer’s disease. It indicates that AD is closely linked to osteoporosis. Triggering osteoblast to clear cellular calcification helps restore calcium homeostasis in cells and has thus shown promising results for AD patients.

Dear Dr. Lee,

Here is an update of the patient with Parkinson’s dis-ease. He is 75 years old, and his Parkinson’s was not hereditary but caused by severe stress from his work. He started out with AIC therapy since October of 2017 without many expectations. However, after others com-mented that he seems to be doing much better, he was encouraged to take it faithfully through November, two doses a day. He said his tremors almost disappeared! After the onset of the disease, his life quality was miser-able but now lives a new life. He came to my church to share the good news with me!

H. Shim

78

DENTIGENFORMULA FOR IMPROVING DENTAL HEALTHAIC therapy raises plasma calcium ion level and stimulates the release of TH and PTH that balances calcium homeostasis and increases the bone turnover rate to build strong bones. This process helps to rebuild alveolar bones of maxillary and mandible, hence increasing the rate of successful implants or periodontal treatments.

When working in conjunction with bone grafts, DentiGen accelerates the rebuilding of extraction sockets, promotes the integration of grafted bones, and assures better osseointegration of implant materials. Complementing bone grafts with DentiGen not only speeds up the procedure but also increases the success rate, even treating severe cases possible for dentists.

Human periodontal ligament stem cells (hPLC) in periodontal ligaments differentiate into root cementum or alveolar bones and are known to be optimally active when the ratio of calcium and phosphorus ions is at 2:1. DentiGen helps the stimulation of hPLC by bringing calcium to phosphorous ratio to this ideal level. DentiGen is also pre-scribed for strengthening loose teeth and for treating diseased gums.

NO BONE GRAFT NEEDED FOR IMPLANT

My dentist extracted my molar tooth with a cavity six months ago. He recommended that I do an implant after a bone graft. I then remembered hearing about DentiGen and told my dentist that I would come back after increasing my jaw bone density. He assured me that there is simply no way to increase jaw bone den-sity. After taking DentiGen for a few months faithfully, I revisited the dentist. He could not believe what he saw in Xrays! He confirmed that the implant is now doable due to increased jaw bone density. Wow!

Soonok C – Female, 47

79

OSSO JRFORMULA FOR OPTIMIZING GROWTH POTENTIALIn Canada, 49% of infants are born calcium deficient. As optimum calcium homeostasis is crucial for healthy cell multiplications, either lack or disturbance of ionic calcium con-centration poses a considerable risk for developing children. Formulated to children’s body weight and needs, Osso Jr implements AIC technology to helps kids to grow to their full potential by building a stronger frame to maintain the more robust immune system by maintaining optimal body pH level, which maximizes oxygen delivery and discourages pathogen proliferation.

Many research linked calcium deficiency in childhood to ADHD and autism, and restor-ing healthy calcium homeostasis using AIC technology offers a good fighting chance. Osso Jr improves the mental focus of children.

Osso Jr helps kids be more energetic naturally to help them be kids more. Use Osso Jr for healthy kids and use MaraGen for treating diseases.

I GREW 17CM IN 8 MONTHS!

I was a short 10th grader with a height of only 153cm (60”). I could only reach my friends’ chins. Then my mother got me Osso Jr in October, 2015. For two months I could not notice any changes. In the past, I had tried so many differ-ent things to grow taller, but none helped, but not having any better options, I decided to try Osso Jr for at least 6 months. Then in January 2016, I started experiencing a dramatic effect, I was growing taller! By August 20, 2016, my official height was 170cm (67”)! Everyone who saw me was amazed. I am amazed. Osso Jr is a miracle for me.

J. Kim - Male, 15, Canada

80

The Pronuvia® trademark is the exclusive property of Pronuvia, Inc. and is registered with the U.S. Patent and Trademark Office.

All other trademarks or registered trademarks are the property of their respective owners. © 2020 Pronuvia, Inc.

Pronuvia.com | AICTherapy.com

To order contact Nutripath, Stephen Heuer at 864-895-6250www.synergisticuniverse.com - [email protected]

AIC THERAPY DOSING · 2021. 1. 9. · MEGAGEN 74 CARTIGEN 75 ALZIGEN 76 DENTIGEN 77 OSSO JR 78. 1...

Documents

Transcript of AIC THERAPY DOSING · 2021. 1. 9. · MEGAGEN 74 CARTIGEN 75 ALZIGEN 76 DENTIGEN 77 OSSO JR 78. 1...